Melevodopa/carbidopa
Alternative Names: Carbidopa/melevodopa; CHF 1512; CNP 1512; GT 1512; Levodopa methyl ester/carbidopa; Sirio; V 1512Latest Information Update: 23 Sep 2021
At a glance
- Originator Chiesi
- Developer Chiesi; Vernalis
- Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Neuroprotectants
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Parkinson's disease
Most Recent Events
- 15 Apr 2021 Discontinued - Phase-II for Parkinson's disease in Europe (PO)
- 15 Apr 2021 Discontinued - Phase-II for Parkinson's disease in USA (PO)
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals